ARS Pharmaceuticals Hits New 52-Week Low at $9.78 Amid Declining Performance

ARS Pharmaceuticals, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 9.78 as of September 15, 2025. This decline marks a significant downturn for the company, which has seen its stock price drop considerably from its 52-week high of USD 18.90.
Over the past year, ARS Pharmaceuticals has reported a performance of -20.59%, starkly contrasting with the S&P 500's gain of 17.67%. The company's market capitalization stands at approximately USD 1,057 million, reflecting its small-cap status. Financial metrics indicate a challenging environment, with a return on equity of -24.97% and a negative debt-to-equity ratio of -1.25.

The company recently announced disappointing results after three consecutive quarters of positive performance, with operating profit hitting a low of USD -47.33 million. Additionally, raw material costs have surged by 29.47% year-over-year, contributing to the financial strain. As ARS Pharmaceuticals navigates these challenges, its current stock performance underscores the volatility and risks associated with its market position.